Johnson & Johnson Vice Chairman of the Executive Committee and Chief Scientific Officer Dr. Paul Stoffels will retire from the company Dec. 31, per an announcement made Oct. 12.
Stoffels called his experience at Johnson & Johnson, during which time he spearheaded the company’s research and product pipeline, “an honor and a privilege.”
“As a physician and a scientist, it is gratifying to see the health care landscape transformed as we unlock the best science and technology to deliver innovative medicines to solve the world’s toughest health challenges,” Stoffels said in a prepared statement. “As I reflect on the work of our talented and dedicated teams around the world, I am proud of the impact we have made and confident that our vibrant community of world-leading scientists and engineers will position our company for continued success.”
Stoffels established Johnson & Johnson Innovation as a critical source to access the best science and technology through strategic partnerships, licensing, acquisitions, incubation and investments; and today, more than 700 companies are incubating in the JLABS ecosystem.
“Paul is an exceptional human being, inspiring people every day. His remarkable capability of bringing a vision and a mission to life, and his commitment to improving and saving lives globally, pulled the organization forward and generated a huge impact on global health and on the trajectory of Johnson & Johnson,” said Alex Gorsky, chairman and CEO of Johnson & Johnson, in a prepared statement. “Together with the senior Johnson & Johnson R&D leaders of the R&D Management Committee, Paul created a culture of people development, sponsorship, entrepreneurial leadership, developing generations of new talented leaders for Johnson & Johnson.”
Stoffels previously held the role of worldwide chairman of pharmaceuticals, and in that post led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Cos. of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation, according to his retirement announcement. He played a key role in collaborations with external partners, including the licensing of key medicines and the acquisition of Crucell and Actelion.
“With Paul at the helm, Janssen rejuvenated its pipeline, launching multiple new medicines, making a difference for people all over the world,” said Joaquin Duato, incoming CEO of Johnson & Johnson. “Under Paul’s leadership, the Janssen R&D teams developed more than 25 new medicines across multiple therapeutic areas. Seven of these medicines have been added to the Essential Medicines List of the World Health Organization, a recognition for the huge impact these medicines are making for patients worldwide.”
During his time with the company, Stoffels established Johnson & Johnson Global Public Health to help people in low- and middle-income countries; and most recently, he spearheaded the 2020 development of the single-dose COVID-19 vaccine.
Earlier in his career, Stoffels was a physician in Africa, focusing on HIV and tropical diseases clinical research, and he worked at Janssen Pharmaceutica under the tutelage of Dr. Paul Janssen in the early 1990s. He re-joined Johnson & Johnson nearly 20 years ago with the acquisition of Virco and Tibotec, where he led the development of several HIV treatment products that transformed a once-devastating, deadly disease into a chronic and treatable condition.
1 of 2
1 article remaining
Advance your business edge with news from NJBiz. Register now for more article access.